after joining the study, a health professional reviews the study information and obtains written agreement to participate.

basic health data are recorded, including age, weight, and details of the congenital heart disease.

vital signs (heart rate, systolic and diastolic blood pressure) are measured and noted.

blood samples are taken to evaluate haematology, chemistry and kidney function.

the medication cangrelor (cangrelor tetrasodium) is prepared as a solution for intravenous infusion.

the prescribed dose is calculated in micrograms per kilogram of body weight and mixed according to the study protocol.

the infusion is begun at the start of the percutaneous vascular procedure.

the medication is delivered continuously through a vein for the duration of the procedure.

the infusion rate follows the dose that was calculated for the patient’s weight.

vital signs are checked regularly while the infusion is running.

the medical team watches for any signs of bleeding, respiratory difficulty, or changes in urine output.

blood samples may be taken during the procedure to assess the effect of the medication on platelet activity.

the infusion is stopped at the completion of the vascular procedure.

the patient remains under observation for at least the next 72 hours.

during this period, vital signs, breathing status, urine output and any bleeding are recorded.

the team evaluates the occurrence of any major, clinically relevant non‑major or minor bleeding as defined by international guidelines.

the need for any blood product transfusion related to the infusion is documented.

laboratory tests are repeated to check kidney function (creatinine) and other blood parameters.

any adverse events, including respiratory symptoms or reduced urine output, are recorded.

after the 72‑hour observation period, the study data are finalized.

the patient receives standard post‑procedure care as usual for congenital heart disease.